Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary-Reference-Cited by-同舟云学术

Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary

Published:2012-06 Issue:6 Volume:43 Page:904-910
ISSN:0046-8177
Container-title:Human Pathology
language:en
Short-container-title:Human Pathology

Author:

Sekiya Ryuichiro,Kajiyama Hiroaki,Sakai Kotaro,Umezu Tomokazu,Mizuno Mika,Shibata Kiyosumi,Yamamoto Eiko,Fujiwara Sawako,Nagasaka Tetsuro,Kikkawa Fumitaka

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference21 articles.

1. International histological classification of tumors. No 9. Histologic typing of ovarian tumors;Serov,1973

2. Surgical pathology of the ovaries;Rusell,1989

3. Ovarian clear cell adenocarcinoma;Kennedy;Gynecol Oncol,1989

4. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy;Sugiyama;Cancer,2000

5. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease;Goff;Gynecol Oncol,1996

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Overview of Ovarian Cancer: The Role of Cancer Stem Cells in Chemoresistance and a Precision Medicine Approach Targeting the Wnt Pathway with the Antagonist sFRP4;Cancers;2023-02-17

2. Isoimperatorin down-regulates epithelial mesenchymal transition through modulating NF-κB signaling and CXCR4 expression in colorectal and hepatocellular carcinoma cells;Cellular Signalling;2022-11

3. Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma;Cancer Research Communications;2022-08-31

4. High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy;BMC Cancer;2022-04-09

5. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy;Investigational New Drugs;2021-01-28